ArticleInfection and immunity1997
Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters.
Article in Infection and immunity, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 86 citations in OpenAlex.
- Vaccination in Leishmaniasis: A Review Article.Iranian biomedical journal · 2022Article
- Evaluation of the Effect of Promoter Type on the Immunogenicity of the Live RecombinantIranian journal of pharmaceutical research : IJPR · 2018Article
- Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.Clinical and vaccine immunology : CVI · 2017Review
- Immunity to intestinal pathogens: lessons learned from Salmonella.Immunological reviews · 2014Review
- Recombinant Salmonella enterica serovar Typhimurium as a vaccine vector for HIV-1 Gag.Viruses · 2013Review
- IFNγ expression by an attenuated strain of Salmonella enterica serovar Typhimurium improves vaccine efficacy in susceptible TLR4-defective C3H/HeJ mice.Medical microbiology and immunology · 2013Article
- Experimental models in vaccine research: malaria and leishmaniasis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2013Review
- Development of Vaccines against Visceral Leishmaniasis.Journal of tropical medicine · 2012Article
- Vaccine Development Against Leishmania donovani.Frontiers in immunology · 2012Article
- Single dose novel Salmonella vaccine enhances resistance against visceralizing L. major and L. donovani infection in susceptible BALB/c mice.PLoS neglected tropical diseases · 2011Article
- Development of protective immunity to Salmonella, a mucosal pathogen with a systemic agenda.Mucosal immunology · 2011Review
- Comparison of a regulated delayed antigen synthesis system with in vivo-inducible promoters for antigen delivery by live attenuated Salmonella vaccines.Infection and immunity · 2011Article
- Salmonella enterica serovar Typhi live vector vaccines finally come of age.Immunology and cell biology · 2009Review
- Influence of promoter, gene copy number, and preexisting immunity on humoral and cellular responses to a vectored antigen delivered by a Salmonella enterica vaccine.Clinical and vaccine immunology : CVI · 2009Article
- Tracking the dynamics of salmonella specific T cell responses.Current topics in microbiology and immunology · 2009Review
- CCR6-mediated dendritic cell activation of pathogen-specific T cells in Peyer's patches.Immunity · 2006Article
- In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes.Clinical and experimental immunology · 2006Article
- Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis.Infection and immunity · 2003Article
- Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice.Infection and immunity · 2002Article
- Regulated antigen expression in live recombinant Salmonella enterica serovar Typhimurium strongly affects colonization capabilities and specific CD4(+)-T-cell responses.Infection and immunity · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The development of Salmonella vaccine vectors has been hindered by both the requirement for multiple doses to induce immune responses and a lack of plasmid stability. Direct comparisons of different promoter systems with the same antigen are necessary to address these important issues. We have previously described an AroA- AroD- deletion mutant of Salmonella typhimurium (GID101) which expresses the gene encoding the Leishmania major promastigote surface glycoprotein gp63 (GID101). While this construct provided significant protection against L. major challenge to highly susceptible BALB/c mice, this required at least two oral doses. We report here the use of two different inducible promoters, the nirB and osmC promoters, to improve vaccine efficacy. These constructs (termed GID105 and GID106, respectively) expressed gp63 in vitro under inducible conditions and colonized BALB/c mice after oral administration. GID105 demonstrated greater plasmid stability in vitro and in vivo than did either GID106 or GID101, which expresses gp63 constitutively. Spleen and lymph node cells from mice immunized with a single oral dose of GID105 proliferated in vitro in response to L. major and secreted gamma interferon, whereas cells from mice given the other constructs did not. Mice immunized with a single oral dose of GID1O5 or GID106 developed significantly smaller lesions upon challenge with L. major, whereas mice administered GID101 did not. Mice administered GID105 also showed considerable resistance to Leishmania donovani infection. These data provide a direct comparison of promoter systems and demonstrate that the use of inducible promoters such as the nirB promoter allows a considerable improvement over the previous vaccine construct in terms of protection against infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.